Aurélien Bourquard (Leuko)
Overview
Aurélien Bourquard is a notable figure in the field of biomedical technology, particularly recognized for his contributions as a co-founder and Chief Data Scientist at Leuko, a medical technology company. Leuko is pioneering non-invasive methods of monitoring white blood cell levels, crucial for patients undergoing chemotherapy. Bourquard's work has been instrumental in developing the technology that allows for the remote monitoring of patients' immune health without the need for blood draws, greatly benefiting those with compromised immune systems.
Recent Developments
- In March 2025, Leuko announced the expansion of its PointCheck platform to include additional biomarkers, augmenting its capabilities beyond white blood cell monitoring.
- August 2024: Leuko received a $4.5 million SBIR Phase IIB award from the National Cancer Institute to further its clinical developments and prepare for regulatory approval and commercialization.
- In June 2024, Bourquard and his team at Leuko completed a successful pivotal study demonstrating the accuracy and usability of their home-use device for remote blood-monitoring, aiming for FDA approval by the year’s end.
- September 2022: Leuko raised $5 million in a Series A funding round, led by prominent venture firms, to advance their clinical trials and technological development for better healthcare outcomes for chemotherapy patients.
Personal Information
| Attribute | Information |
|---|---|
| Full Name | Aurélien Bourquard |
| Born | Not Publicly Available |
| Nationality | Not Publicly Available |
| Occupation | Chief Data Scientist & Co-founder of Leuko |
| Known For | Non-invasive biomedical monitoring technology |
| Net Worth | Not Publicly Available |
| Education | PhD, Swiss Federal Institute of Technology, Lausanne |
Early Life and Education
Details on Aurélien Bourquard's childhood and early life are not extensively available. However, it is known that he pursued his higher education at the Swiss Federal Institute of Technology, Lausanne, where he received his PhD focusing on computational optics and signal processing. His academic journey laid a solid foundation in signal processing and biomedical application, eventually steering his career towards advanced biomedical imaging and non-invasive diagnostics.
Career and Notable Achievements
Aurélien Bourquard's professional journey is marked by significant achievements in biomedical technology:
- 2013-2018: Worked as a Postdoctoral Research Fellow at the Massachusetts Institute of Technology (MIT), focusing on new algorithm designs for biomedical imaging.
- 2017: Co-founded Leuko, inspired by his research at MIT, aiming to revolutionize how white blood cell conditions are monitored.
- Developments: Led the development of non-invasive devices utilizing AI for detecting neutropenia —a condition of low white blood cell count.
- Recognition: Under his leadership, Leuko's technology received multiple awards and recognitions, including NIH grants and venture capital investments.
Current Work and Impact
As of 2025, Aurélien Bourquard continues to lead innovation at Leuko as the Chief Data Scientist. His work is transforming patient care by making critical immune system measurements more accessible globally. The impact of his technology is profound, especially among cancer patients who benefit from his non-invasive diagnostics that reduces the frequency of hospital visits and enhances the management of chemotherapy's side effects.
Conclusion
Aurélien Bourquard's contributions to biomedical technology through his work at Leuko are making significant strides in non-invasive patient monitoring. His innovations promise to reduce healthcare costs and increase the accessibility of patient diagnostics, potentially transforming cancer care and broader healthcare practices. As his work progresses, it promises to leave lasting impacts on biomedical monitoring technologies, setting new standards for patient care.